JP2015134758A5 - - Google Patents

Download PDF

Info

Publication number
JP2015134758A5
JP2015134758A5 JP2015002795A JP2015002795A JP2015134758A5 JP 2015134758 A5 JP2015134758 A5 JP 2015134758A5 JP 2015002795 A JP2015002795 A JP 2015002795A JP 2015002795 A JP2015002795 A JP 2015002795A JP 2015134758 A5 JP2015134758 A5 JP 2015134758A5
Authority
JP
Japan
Prior art keywords
peptide
amino acid
acid sequence
peptide according
tfpi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015002795A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015134758A (ja
JP6195858B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2015134758A publication Critical patent/JP2015134758A/ja
Publication of JP2015134758A5 publication Critical patent/JP2015134758A5/ja
Application granted granted Critical
Publication of JP6195858B2 publication Critical patent/JP6195858B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015002795A 2010-03-19 2015-01-09 Ｔｆｐｉ阻害剤および使用方法 Active JP6195858B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31575810P 2010-03-19 2010-03-19
US61/315,758 2010-03-19

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2013500053A Division JP5730983B2 (ja) 2010-03-19 2011-02-11 Ｔｆｐｉ阻害剤および使用方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017055402A Division JP2017105851A (ja) 2010-03-19 2017-03-22 Ｔｆｐｉ阻害剤および使用方法

Publications (3)

Publication Number Publication Date
JP2015134758A JP2015134758A (ja) 2015-07-27
JP2015134758A5 true JP2015134758A5 (cg-RX-API-DMAC7.html) 2015-11-26
JP6195858B2 JP6195858B2 (ja) 2017-09-13

Family

ID=44649759

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013500053A Active JP5730983B2 (ja) 2010-03-19 2011-02-11 Ｔｆｐｉ阻害剤および使用方法
JP2015002795A Active JP6195858B2 (ja) 2010-03-19 2015-01-09 Ｔｆｐｉ阻害剤および使用方法
JP2017055402A Pending JP2017105851A (ja) 2010-03-19 2017-03-22 Ｔｆｐｉ阻害剤および使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2013500053A Active JP5730983B2 (ja) 2010-03-19 2011-02-11 Ｔｆｐｉ阻害剤および使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017055402A Pending JP2017105851A (ja) 2010-03-19 2017-03-22 Ｔｆｐｉ阻害剤および使用方法

Country Status (12)

Country Link
US (5) US8450275B2 (cg-RX-API-DMAC7.html)
EP (2) EP3146977B1 (cg-RX-API-DMAC7.html)
JP (3) JP5730983B2 (cg-RX-API-DMAC7.html)
KR (2) KR101784030B1 (cg-RX-API-DMAC7.html)
CN (2) CN103025345B (cg-RX-API-DMAC7.html)
AU (1) AU2011227714B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012023559A2 (cg-RX-API-DMAC7.html)
CA (1) CA2793465C (cg-RX-API-DMAC7.html)
DK (1) DK2547355T3 (cg-RX-API-DMAC7.html)
ES (2) ES2983470T3 (cg-RX-API-DMAC7.html)
NZ (3) NZ603028A (cg-RX-API-DMAC7.html)
WO (1) WO2011115712A2 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104984319B (zh) 2008-12-19 2025-05-09 武田药品工业株式会社 Tfpi抑制剂和使用方法
HUE047173T2 (hu) 2010-03-01 2020-04-28 Bayer Healthcare Llc Optimalizált monoklonális ellenanyagok szöveti faktor útvonal inhibitor (TFPI) ellen
EP3146977B1 (en) 2010-03-19 2024-05-08 Takeda Pharmaceutical Company Limited Tfpi inhibitors and methods of use
KR102263685B1 (ko) 2012-03-21 2021-06-11 다케다 야쿠힌 고교 가부시키가이샤 Tfpi 저해제 및 사용 방법
EP3563872A1 (en) 2012-04-05 2019-11-06 Massachusetts Institute Of Technology Immunostimulatory compositions and methods of use thereof
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
JP2016514687A (ja) * 2013-03-15 2016-05-23 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビターに対するプロドラッグ抗体
JP6584397B2 (ja) 2013-07-19 2019-10-02 ノヴォ ノルディスク アー／エス 凝血促進活性を誘発することができる組織因子経路インヒビターのｎ末端部分を認識する抗体
US9580758B2 (en) 2013-11-12 2017-02-28 Luc Montagnier System and method for the detection and treatment of infection by a microbial agent associated with HIV infection
SG10201807066UA (en) 2014-02-28 2018-09-27 3B Pharmaceuticals Gmbh Peptides and methods of use
US10300154B2 (en) 2014-09-17 2019-05-28 David R Elmaleh Anticoagulant derivatives for cardiovascular imaging
SG10201912817YA (en) * 2015-08-19 2020-02-27 Pfizer Tissue factor pathway inhibitor antibodies and uses thereof
US11739163B2 (en) 2016-09-29 2023-08-29 Aebi Ltd. Therapeutic multi-targeting constructs and uses thereof
US12247052B2 (en) 2018-03-02 2025-03-11 Elicio Therapeutics, Inc. CpG amphiphiles and uses thereof
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물
CN112840032A (zh) * 2018-10-04 2021-05-25 血栓形成和凝血公司 用于确定蛋白水平的方法
WO2020191305A2 (en) 2019-03-20 2020-09-24 Massachusetts Institute Of Technology Uses of amphiphiles in immune cell therapy and compositions therefor
CN118406106A (zh) 2019-07-08 2024-07-30 3B制药有限公司 包含成纤维细胞活化蛋白配体的化合物及其用途
CN118613492A (zh) * 2022-01-30 2024-09-06 西湖大学 Tfpi结合多肽及其用途
WO2023170680A1 (en) 2022-03-08 2023-09-14 Equashield Medical Ltd Fluid transfer station in a robotic pharmaceutical preparation system

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
JPS607193A (ja) 1983-06-25 1985-01-14 古河電気工業株式会社 回路基板用半田付炉
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
JPS6153985A (ja) 1984-08-25 1986-03-18 松下電工株式会社 ブラインド
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4966852A (en) 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
IL87171A (en) 1987-11-23 1995-08-31 Monsanto Co cDNA of human tissue factor inhibitor
US5663143A (en) 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
US5219994A (en) 1988-11-08 1993-06-15 W. Alton Jones Cell Science Center, Inc. Inhibitor of tissue factor activity
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
US5622988A (en) 1990-06-15 1997-04-22 Novo Nordisk A/S Use of a low molecular weight metabolite from fungus for reducing prolonged coagulation time
DK146190D0 (da) 1990-06-15 1990-06-15 Novo Nordisk As Hidtil ukendte forbindelser
US5849703A (en) 1990-08-27 1998-12-15 G. D. Searle & Co. Pre-formed anticoagulant heparin/TFPI complexes
DK261490D0 (da) 1990-10-31 1990-10-31 Novo Nordisk As New pharmaceutical compound
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
JPH04252954A (ja) 1991-01-29 1992-09-08 Asahi Chem Ind Co Ltd タンパクの測定方法、試薬及びキット
US5997864A (en) 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
EP0539975A1 (en) 1991-10-31 1993-05-05 Teijin Limited Method for immunological assay of free lipoprotein-associated coagulation inhibitor (LACI) and kit therefor
JPH067193A (ja) 1991-11-29 1994-01-18 Teijin Ltd モノクローナル抗体
IL104325A (en) 1992-01-07 2000-10-31 Novo Nordisk As Variants of human kunitz-type protease inhibitor domain II of tissue factor pathway inhibitor (TFPI) pharmaceutical compositions containing them a DNA construct encoding them their expression vectors a cell containing said DNA constructs and methods for the production of all the above
IL104324A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
IL104326A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
IL104314A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Human kunitz-type protease inhibitor and variants thereof,their production and pharmaceutical compositions containing them
IL104327A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
EP0651655A4 (en) 1992-07-24 1996-05-29 Oklahoma Med Res Found REDUCTION OF MICROVASCULAR BLEEDING DURING SURGERY BY BLOCKING PROTEIN C ACTIVATION
JPH06153985A (ja) 1992-11-16 1994-06-03 Teijin Ltd モノクローナル抗体
BR9405798A (pt) 1993-02-22 1995-12-12 Vivorx Pharmaceuticals Inc Métodos para liberação in vivo de material biológico e composições úteis dos mesmos
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
EP0719334A1 (en) 1993-09-14 1996-07-03 Genentech, Inc. Pharmaceutical compositions containing ecotin and homologs thereof
US5455338A (en) 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
ATE529444T1 (de) 1994-01-11 2011-11-15 Dyax Corp Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten
US5902582A (en) 1995-09-05 1999-05-11 Chiron Corporation Use of TFPI inhibitor for treatment of cancer
JP3681206B2 (ja) 1995-12-26 2005-08-10 株式会社三菱化学ヤトロン 抗ファクターＸａ・ティシュファクターパスウェイインヒビター複合体モノクローナル抗体及びその使用
WO1997035609A1 (en) 1996-03-25 1997-10-02 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Neovascularization inhibitor containing tissue factor pathway inhibitor
WO1998033920A2 (en) 1997-01-31 1998-08-06 Human Genome Sciences, Inc. Tissue factor pathway inhibitor-3
US20050032690A1 (en) 1997-09-10 2005-02-10 Rojkjaer Lisa Payne Factor VII polypeptides for preventing formation of inhibitors in subjects with haemophilia
WO1999042119A1 (en) 1998-02-18 1999-08-26 Harbor-Ucla Research And Education Institute Antimicrobial peptides and derived metapeptides
JP2000128803A (ja) 1998-10-19 2000-05-09 Shionogi & Co Ltd ティッシュ・ファクター・パスウェイ・インヒビター−２抗体
JP2003505678A (ja) 1999-07-23 2003-02-12 ザ スクリップス リサーチ インスティテュート 全血の凝固因子活性を測定する方法
US6180607B1 (en) 1999-08-05 2001-01-30 Christopher Davies Protein having proteinase inhibitor activity
US6458387B1 (en) 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
AU1615701A (en) 1999-11-16 2001-05-30 General Hospital Corporation, The Compositions and methods for regulating tumor-associated antigen expression
US6821775B1 (en) 2000-02-11 2004-11-23 Genvec, Inc. Viral vector encoding pigment epithelium-derived factor
US7015194B2 (en) 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
ATE300953T1 (de) * 2000-05-10 2005-08-15 Novo Nordisk Healthcare Ag Verwendung von faktor vii-a und faktor xiii enthaltenden pharmazeutischen verbindungen
DE60133271T2 (de) 2000-05-16 2009-04-23 Genentech, Inc., South San Francisco Behandlung von knorpelerkrankungen
WO2002033089A2 (en) 2000-10-05 2002-04-25 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Ixodes scapularis tissue factor pathway inhibitor
DE60138641D1 (de) 2000-10-27 2009-06-18 Baxter Healthcare Sa Herstellung von mikrokügelchen
US20030040480A1 (en) 2001-07-20 2003-02-27 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides
MXPA04000415A (es) 2001-07-20 2004-11-22 Novo Nordisk Healthcare Ag Composicion farmaceutica que comprende polipeptidos del factor vii y polipeptidos del factor xi.
ATE395042T1 (de) 2001-08-16 2008-05-15 Baxter Int Darreichungsformen welche mikropartikel und treibgas enthalten
US20080026068A1 (en) 2001-08-16 2008-01-31 Baxter Healthcare S.A. Pulmonary delivery of spherical insulin microparticles
US20030124132A1 (en) 2001-09-27 2003-07-03 Board Of Regents, The University Of Texas System Combined compositions for tumor vasculature coaguligand treatment
WO2003039579A1 (en) 2001-11-09 2003-05-15 Novo Nordisk Health Care Ag Pharmaceutical composition comprising factor vii polypeptides and tafi polypeptides
US7291587B2 (en) 2001-11-09 2007-11-06 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and TAFI polypeptides
US20050214836A1 (en) 2002-08-30 2005-09-29 Oncotherapy Science, Inc. Method of diagnosing ovarian endometriosis
AU2003265866A1 (en) 2002-09-03 2004-03-29 Vit Lauermann Targeted release
EP1403638A1 (en) 2002-09-25 2004-03-31 Mondobiotech SA Molecular methods for diagnosing interstitial lung diseases
PT1587907E (pt) 2003-01-07 2011-04-08 Dyax Corp Biblioteca de domínios de kunitz
AU2003229678A1 (en) 2003-04-15 2004-11-04 Dirk Koczan Method for diagnosing rheumatoid arthritis or osteoarthritis
US20070092452A1 (en) 2003-07-18 2007-04-26 Julia Rashba-Step Methods for fabrication, uses, compositions of inhalable spherical particles
KR101137785B1 (ko) 2003-07-18 2012-04-25 백스터 인터내셔널 인코포레이티드 제어된 상 분리에 의해 제조된 작은 구형 입자의 제조방법, 이용 방법 및 조성물
US20050142205A1 (en) 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
AU2004258971A1 (en) 2003-07-22 2005-02-03 Baxter Healthcare S.A. Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof
ES2381110T3 (es) 2003-09-09 2012-05-23 Novo Nordisk Health Care Ag Polipéptidos de factor VII de coagulación
EP1664291B1 (en) 2003-09-09 2012-02-29 Novo Nordisk Health Care AG Coagulation factor vii polypeptides
JP4603548B2 (ja) 2003-09-24 2010-12-22 オンコセラピー・サイエンス株式会社 Ｔｆｐｉ−２タンパク質を用いた卵巣子宮内膜症の診断法
CA2540382C (en) 2003-09-29 2012-03-06 Hemoteq Gmbh Biocompatible, biostable coating of medical surfaces
US20090232866A1 (en) 2003-10-07 2009-09-17 Mariann Pavone-Gyongyosi Oligopeptides as coating material for medical products
BRPI0416201A (pt) * 2003-11-20 2006-12-26 Sanofi Pasteur Inc métodos para purificação de toxina coqueluche e peptìdios neles utilizáveis
US20050181978A1 (en) 2003-11-20 2005-08-18 Rasmus Rojkjaer Therapeutic use of factor XI
JP2007513881A (ja) 2003-11-20 2007-05-31 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｘｉ因子の治療学的使用
US20050147689A1 (en) 2003-12-30 2005-07-07 Egilmez Nejat K. Method for inhibiting the growth of gastrointestinal tract tumors
WO2005082434A2 (de) 2004-02-28 2005-09-09 Hemoteq Gmbh Biokompatible beschichtung, verfahren und verwendung von medizinischen oberflächen
JP2007537205A (ja) 2004-05-11 2007-12-20 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 熱傷外傷の治療のためのＶＩＩａ因子の使用
US8728525B2 (en) 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
MXPA06012992A (es) 2004-05-12 2007-02-12 Baxter Int Microesferas que comprenden proteina y que muestran inyectabilidad en altas concentraciones de este agente.
WO2005115442A1 (en) 2004-05-25 2005-12-08 Novo Nordisk Health Care Ag Use of coagulation factor xiii for treatment of post surgical bleedings
ES2482105T3 (es) 2004-05-27 2014-08-01 Baxter International Inc. Procedimientos de tratamiento de trastornos hemorrágicos utilizando polisacáridos sulfatados
US20080058255A1 (en) 2004-06-21 2008-03-06 Novo Nordisk Healthcare A/G Glycosylation-Disrupted Factor VII Variants
US20090004175A1 (en) 2004-07-16 2009-01-01 Novo Nordick Health Care A/G Methods for Optimizing Forming Vlla-Based Hemostatic Treatment
US20060040896A1 (en) 2004-08-18 2006-02-23 Paringenix, Inc. Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity
JP4252954B2 (ja) 2004-12-02 2009-04-08 インターナショナル・ビジネス・マシーンズ・コーポレーション 情報処理装置、情報処理装置のパワーマネージメント方法、およびそのためのプログラム
EP1855712A2 (en) 2005-02-28 2007-11-21 Novo Nordisk Health Care AG Fxiii variants with improved properties
CN101184775A (zh) 2005-03-04 2008-05-21 伊利诺斯大学理事会 凝血及纤溶级联系统的调控剂
CN101188996B (zh) 2005-04-27 2013-03-27 巴克斯特国际公司 表面改性的微粒及其形成和使用方法
KR20080008364A (ko) 2005-05-05 2008-01-23 헤모텍 아게 관 스텐트의 전면 코팅
WO2006128497A1 (en) 2005-06-01 2006-12-07 Novo Nordisk A/S Pharmaceutical formulation of factor xi
EP1919499A2 (en) 2005-07-29 2008-05-14 Universiteit van Maastricht Regulation of tissue factor activity by protein s and tissue factor pathway inhibitor
DE102005039579B4 (de) 2005-08-19 2022-06-30 Magforce Ag Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen
GB0525999D0 (en) 2005-12-21 2006-02-01 Ares Trading Sa Novel members of the kazal family of serine protease inhibitors
DE112007000906A5 (de) 2006-02-09 2009-01-15 B. Braun Melsungen Ag Faltenballonbeschichtungsverfahren
US20070192033A1 (en) 2006-02-16 2007-08-16 Microsoft Corporation Molecular interaction predictors
US9096839B2 (en) 2006-04-26 2015-08-04 Arteriocyte Medical Systems, Inc. Compositions and methods of preparation thereof
US20070281031A1 (en) 2006-06-01 2007-12-06 Guohan Yang Microparticles and methods for production thereof
EP1892303A1 (en) 2006-08-22 2008-02-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Methods for identifying therapeutical targets in tumors and for determining and targeting angiogenesis and hemostasis related to adenocarcinomas of the lung
EP1895436A1 (en) * 2006-08-31 2008-03-05 Silicos NV Method for evolving molecules and computer program for implementing the same
EP1913962A1 (en) 2006-10-22 2008-04-23 Ophir Perelson Expandable medical device for the treatment and prevention of cardiovascular diseases
EP2121767B1 (en) 2007-02-23 2014-04-09 Baxter International Inc. Process methods for fucoidan purification from seaweed extracts
EP1972687A1 (en) 2007-03-23 2008-09-24 GenOdyssee Polynucleotides and polypeptides of human factor VII gene, SNPs
US20100137211A1 (en) 2007-04-11 2010-06-03 Monahan Paul E Methods and compositions for intra-articular coagulation proteins
DK2915564T3 (da) 2007-09-28 2021-02-08 Alexion Pharma Inc Antidoter mod faktor XA-inhibitorer og fremgangsmåder til anvendelse deraf
WO2009061697A1 (en) 2007-11-09 2009-05-14 The Board Of Trustees Of The University Of Illinois Anticoagulant antagonist and hemophilia procoagulant
EP2231702A1 (en) 2007-12-21 2010-09-29 Ifxa A/s Protease inhibitor
FR2934052B1 (fr) 2008-07-17 2011-11-25 Stago Diagnostica Dosage de l'activite du facteur tissulaire circulant
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
KR20110039348A (ko) 2008-08-06 2011-04-15 노보 노르디스크 헬스 케어 악티엔게젤샤프트 연장된 생체내 효능을 가지는 콘쥬게이트된 단백질
KR100994996B1 (ko) 2008-08-06 2010-11-18 한국과학기술연구원 페난트렌 노출 여부 확인용 바이오마커 및 이를 이용한확인 방법
CN104984319B (zh) 2008-12-19 2025-05-09 武田药品工业株式会社 Tfpi抑制剂和使用方法
EP3146977B1 (en) 2010-03-19 2024-05-08 Takeda Pharmaceutical Company Limited Tfpi inhibitors and methods of use
EA201991704A3 (ru) 2011-04-01 2020-06-30 Байер Хелфкеа Ллк Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)

Similar Documents

Publication Publication Date Title
JP2015134758A5 (cg-RX-API-DMAC7.html)
CN104984319B (zh) Tfpi抑制剂和使用方法
JP2018509935A5 (cg-RX-API-DMAC7.html)
JP2016501829A5 (cg-RX-API-DMAC7.html)
FI3430027T3 (fi) Peptidi käytettäväksi ei-pienisoluisen keuhkosyövän ja pienisoluisen keuhkosyövän hoidossa
JP2009509535A5 (cg-RX-API-DMAC7.html)
JP2011502479A5 (cg-RX-API-DMAC7.html)
JP2013127002A5 (cg-RX-API-DMAC7.html)
JP2018171063A5 (cg-RX-API-DMAC7.html)
FI2970398T3 (fi) Rsv f -prefuusioproteiineja ja niiden käyttö
JP2015525217A5 (cg-RX-API-DMAC7.html)
JP2010534486A5 (cg-RX-API-DMAC7.html)
JP2019507589A5 (cg-RX-API-DMAC7.html)
JP2017537622A5 (cg-RX-API-DMAC7.html)
JP2009529509A5 (cg-RX-API-DMAC7.html)
JP2012082206A5 (cg-RX-API-DMAC7.html)
JP2015509097A5 (cg-RX-API-DMAC7.html)
JP2016512213A5 (cg-RX-API-DMAC7.html)
JP2018508492A5 (cg-RX-API-DMAC7.html)
JP2015522264A5 (cg-RX-API-DMAC7.html)
JP2006523711A5 (cg-RX-API-DMAC7.html)
JP2019534884A5 (cg-RX-API-DMAC7.html)
JP2016531583A5 (cg-RX-API-DMAC7.html)
FI3448879T3 (fi) Claudin-6 -peptidejä
RU2018128613A (ru) Мутированный фактор фон виллебранда